Literature DB >> 33084922

Prognostic value of pretreatment inflammatory markers in variant histologies of the bladder: is inflammation linked to survival after radical cystectomy?

Severin Rodler1, Alexander Buchner2, Stephan T Ledderose3, Lennert Eismann2, Yannic Volz2, Paulo Pfitzinger2, Alexander Kretschmer2, Gerald B Schulz2, Alexander Karl4, Boris Schlenker2, Christian G Stief2, Friedrich Jokisch2.   

Abstract

PURPOSE: To investigate differences in standard preoperative inflammatory markers in patients with urothelial carcinoma (UC) and variant histologies undergoing radical cystectomy (RC) and determine its impact on survival.
METHODS: Patients undergoing RC at an academic high-volume center were retrospectively analyzed. Preoperatively taken CRP, leukocytes, hemoglobin (Hb), and thrombocytes were analyzed as routine inflammatory biomarkers. Log-rank tests and Kruskal-Wallis analysis were used to calculate for differences in survival and in blood levels of biomarkers.
RESULTS: 886 patients with complete follow-up and UC or variant histology underwent RC at our institution between 2004 and 2019. Although variant histology presents with significantly higher t stage than UC, cancer-specific survival (CSS) of UC (1-year-CSS: 93%) is not significantly different to variant histology of UC with squamous differentiation (UCSD, 1-year-CSS: 81%), squamous cell carcinoma (SCC, 1-year-CSS: 82%), and adenocarcinoma (AC, 1-year-CSS: 81%). In UC, alterations in all biomarkers except leukocytes beyond routine cut-off values were associated with poor survival (p < 0.01), whereas Hb beyond cut-off values are associated with poor prognosis in SCC (p < 0.05). CRP levels are significantly elevated in UCSD and SCC at time of surgery compared to UC (p < 0.05).
CONCLUSION: Inflammatory biomarkers reveal distinctive patterns across UC and variant histologies of bladder cancer. As inflammation might play an important role in cancer progression, further research is warranted to understand those molecular mechanisms and their potential therapeutic impact in variant histology of bladder cancer.
© 2020. Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Biomarker; Patient selection; Radical cystectomy; Variant histology

Mesh:

Substances:

Year:  2020        PMID: 33084922     DOI: 10.1007/s00345-020-03482-8

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  6 in total

1.  Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration.

Authors:  Chiara Lonati; Luca Afferi; Andrea Mari; Andrea Minervini; Wojciech Krajewski; Marco Borghesi; Gerald B Schulz; Michael Rink; Francesco Montorsi; Alberto Briganti; Renzo Colombo; Alberto Martini; Andrea Necchi; Roberto Contieri; Rodolfo Hurle; Paolo Umari; Stefania Zamboni; Claudio Simeone; Francesco Soria; Giancarlo Marra; Paolo Gontero; Jeremy Yuen-Chun Teoh; Tobias Klatte; Anne-Sophie Bajeot; Mathieu Roumiguié; Morgan Rouprêt; Alexandra Masson-Lecomte; Ekaterina Laukhtina; Anne Sophie Valiquette; M Carmen Mir; Alessandro Antonelli; Sarah M H Einerhand; Kees Hendricksen; Roberto Carando; Christian D Fankhauser; Philipp Baumeister; Agostino Mattei; Shahrokh F Shariat; Marco Moschini
Journal:  World J Urol       Date:  2022-02-26       Impact factor: 4.226

2.  Development of nomograms related to inflammatory biomarkers to estimate the prognosis of bladder cancer after radical cystectomy.

Authors:  Wentao Zhang; Fuhan Yang; Aimaitiaji Kadier; Yifan Chen; Yang Yu; Junfeng Zhang; Jiang Geng; Yang Yan; Wei Li; Xudong Yao
Journal:  Ann Transl Med       Date:  2021-09

Review 3.  The Role of C-Reactive Protein in Kidney, Bladder, and Prostate Cancers.

Authors:  Daniel O'Brian; Megan Prunty; Alexander Hill; Jonathan Shoag
Journal:  Front Immunol       Date:  2021-08-27       Impact factor: 7.561

4.  Outcomes and Prognostic Factors of Patients with Urothelial Carcinoma Undergoing Radical Cystectomy and pT0 in the Final Histology Without Neoadjuvant Chemotherapy.

Authors:  Severin Rodler; Alexander Buchner; Lennert Eismann; Gerald Bastian Schulz; Julian Marcon; Stephan Ledderose; Boris Schlenker; Christian G Stief; Alexander Karl; Jan-Friedrich Jokisch
Journal:  Res Rep Urol       Date:  2022-08-01

5.  Identification of the Tumor Infiltrating Lymphocytes (TILs) Landscape in Pure Squamous Cell Carcinoma of the Bladder.

Authors:  Lennert Eismann; Severin Rodler; Alexander Buchner; Gerald Bastian Schulz; Yannic Volz; Robert Bischoff; Benedikt Ebner; Thilo Westhofen; Jozefina Casuscelli; Raphaela Waidelich; Christian Stief; Boris Schlenker; Stephan Ledderose
Journal:  Cancers (Basel)       Date:  2022-08-18       Impact factor: 6.575

Review 6.  Immune status for monitoring and treatment of bladder cancer.

Authors:  Shen Pan; Shijie Li; Yunhong Zhan; Xiaonan Chen; Ming Sun; Xuefeng Liu; Bin Wu; Zhenhua Li; Bitian Liu
Journal:  Front Immunol       Date:  2022-09-08       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.